China Drugmakers Face U.S. Scrutiny on Investigator Bump

U.S. regulators are more than tripling to 27 the number of workers they’ll have in China to inspect pharmaceutical plants and products, a move that may spur a wave of enforcement similar to what’s happening in India.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.